The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
This study evaluated a difficult-to-treat Crohn's disease patient population
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
